By the end of January 2013, the employee elected Board member Mads P.G. Korsgaard will resign from the Board of Directors of NeuroSearch A/S (NEUR) due to the expiration of his employment with the company.
With effect from 1 February 2013, IT Director Morten Henrik Nielsen will re-join the Board as employee elected Board member.
Morten Henrik Nielsen was employed at NeuroSearch in 1989 and was a member of the Board of Directors for some time in 2012.
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II and NS2359 which has completed phase I.
All drug candidates exert their effect in the central nervous system.
(Unknown - 271 x 175)
NeuroSearch A/S Logo